This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.


August 7th, 2023

Company name: Modalis Therapeutics Corporation
Stock exchange listing: Tokyo Stock Exchange
Code number: 4883
URL: https://www.modalistx.com/en/
Representative: Haruhiko Morita

Notice of pipeline consolidation

Modalis Therapeutics Corporation (hereafter, "the Company") hereby announces that the Company has consolidated its development pipeline as it regained rights of MDL-201 and MDL-202 from Astellas Pharma Inc.

MDL-201 and MDL-202 are programs that have been developed for muscle diseases, DMD (Duchenne Muscular Dystrophy) and DM1 (Myotonic Dystrophy type 1), respectively. These programs have been developed for these diseases based on the CRISPR-GNDM® platform and will be developed in a new version with a muscle-selective capsid.
With the acquisition of this pipeline, we have decided to reorganize our pipeline as figure below, taking into consideration our resources and other factors, and to delete MDL-102 and MDL-205, while adding MDL-103 for FSHD (facioscapulohumeral muscular dystrophy), which we have been studying.
This matter shall have a minor or no impact on our business performance for the fiscal year ending December 2023.



*1: LAMA2-related congenital muscular dystrophy
*2: Myotonic Dystrophy Type 1
*3: Duchene Muscular Dystrophy
*4: facioscapulohumeral muscular dystrophy
*5: Dilated Cardiomyopathy